Merck feels pain of Schering ops integration

Difficulties integrating the manufacturing and supply chain operations of two big pharma companies is crimping the supply of women's health products. As Merck continues to swallow Schering-Plough following the late 2009 acquisition, legacy systems and processes are proving a hindrance to efforts aimed at operations consistency.

The drugmaker says it's been managing through temporary supply shortages of some women's health products since the end of last year, Dow Jones reports. It's "working to resolve these issues."

Plans announced last year included the closing of eight manufacturing plants as well as R&D sites for cost savings. The news outlet reports Merck has also faced manufacturing and supply problems in its vaccine operations.

- here's the story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.